Cargando…
Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials
PURPOSE: To evaluate the efficacy and safety of subcutaneous (SC) methylnaltrexone for opioid-induced constipation (OIC) in patients with and without active cancer. PATIENTS AND METHODS: We analyzed two randomized, double-blind, placebo-controlled, Phase 3/4 trials (NCT00402038, NCT00672477). Patien...
Autores principales: | Shah, Eric D, Chamberlain, Bruce H, Rhiner, Michelle, Slatkin, Neil E, Stambler, Nancy, Israel, Robert J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926929/ https://www.ncbi.nlm.nih.gov/pubmed/36798078 http://dx.doi.org/10.2147/JPR.S366460 |
Ejemplares similares
-
Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies
por: Chamberlain, Bruce H, et al.
Publicado: (2021) -
Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose
por: Chamberlain, Bruce H, et al.
Publicado: (2023) -
Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Rauck, Richard L, et al.
Publicado: (2018) -
Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials
por: Mehta, Neel, et al.
Publicado: (2023) -
Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness
por: Mehta, Neel, et al.
Publicado: (2023)